| scholarly article | Q13442814 |
| P2093 | author name string | Samy Suissa | |
| Pierre Ernst | |||
| Abbas Kezouh | |||
| P2860 | cites work | Association of inhaled corticosteroid use with cataract extraction in elderly patients. | Q50870339 |
| Inhaled and Nasal Corticosteroid Use and the Risk of Fracture | Q51649420 | ||
| Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. | Q53343713 | ||
| Chronic Obstructive Pulmonary Disease, Asthma, and Risk of Type 2 Diabetes in Women | Q57749967 | ||
| Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia | Q80076108 | ||
| Use of combination therapy in asthma: are they prescribed according to guidelines | Q80608453 | ||
| Low-dose inhaled and nasal corticosteroid use and the risk of cataracts | Q82565509 | ||
| Inhaled corticosteroids in COPD: a case in favour | Q84148155 | ||
| Inhaled corticosteroids in COPD: the case against | Q84148157 | ||
| Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease | Q22299313 | ||
| Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 | ||
| Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis | Q33634936 | ||
| The global burden of chronic diseases: overcoming impediments to prevention and control | Q34323994 | ||
| Inhaled corticosteroids and the risk of diabetes among the elderly | Q34524994 | ||
| The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease | Q34546085 | ||
| Epidemiology and costs of chronic obstructive pulmonary disease. | Q34563833 | ||
| The association of inhaled corticosteroid use with serum glucose concentration in a large cohort | Q34606671 | ||
| Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma | Q34738227 | ||
| Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly | Q34743366 | ||
| Potential adverse effects of the inhaled corticosteroids | Q35298305 | ||
| Relationship between asthma severity and obesity | Q35883882 | ||
| Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. | Q46562371 | ||
| The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide | Q46966092 | ||
| Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease | Q48487432 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1001-1006 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Inhaled corticosteroids and the risks of diabetes onset and progression | |
| Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression | |||
| P478 | volume | 123 |
| Q38131332 | 'SIMPLES': a structured primary care approach to adults with difficult asthma. |
| Q47138049 | A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. |
| Q26801661 | A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease |
| Q41464320 | Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol |
| Q47728819 | An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? |
| Q36332206 | Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice |
| Q41184141 | Asthma referrals: a key component of asthma management that needs to be addressed |
| Q40365428 | Body mass index, adipokines and insulin resistance in asthmatic children and adolescents |
| Q37941499 | COPD and the metabolic syndrome: an intriguing association. |
| Q30251770 | Challenges in the pharmacological treatment of geriatric asthma. |
| Q35765263 | Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly |
| Q33709357 | Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia |
| Q37193551 | Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications |
| Q26799659 | Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management |
| Q45043975 | Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease |
| Q36237935 | Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes |
| Q39497381 | Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Ob |
| Q88075949 | Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore |
| Q40598255 | Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. |
| Q41443181 | Defining COPD-Related Comorbidities, 2004-2014. |
| Q90083689 | Defining severe obstructive lung disease in the biologic era: an endotype-based approach |
| Q41432972 | Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies |
| Q35538249 | Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines |
| Q90668963 | Do Benefits Outweigh Risks for Corticosteroid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in People with Diabetes Mellitus? |
| Q35703369 | Does my patient have asthma? |
| Q35056185 | Effect of inhaled corticosteroids on glycemic status |
| Q36802786 | Effect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study |
| Q54467741 | Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. |
| Q26747066 | Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms |
| Q86716933 | Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly |
| Q35939395 | Exploring the impact of chronic obstructive pulmonary disease (COPD) on diabetes control in diabetes patients: a prospective observational study in general practice |
| Q47300605 | Fluoroquinolones and the risk of serious arrhythmia: a population-based study |
| Q34550471 | Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary |
| Q47984024 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary |
| Q96618151 | Glycated hemoglobin A1c, lung function, and hospitalizations among adults with asthma |
| Q38095559 | How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? |
| Q90686358 | Hypertension and diabetes mellitus as risk factors for asthma in Korean adults: the Sixth Korea National Health and Nutrition Examination Survey |
| Q47722491 | Inappropriate inhaled corticosteroid prescribing in chronic obstructive pulmonary disease patients |
| Q91902261 | Incidence of type II diabetes in chronic obstructive pulmonary disease: a nested case-control study |
| Q92143341 | Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis |
| Q35056151 | Inhalational Steroids and Iatrogenic Cushing's Syndrome |
| Q40244225 | Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)-The OUTPUL Study |
| Q36988673 | Inhaled Corticosteroids Use Is Not Associated With an Increased Risk of Pregnancy-Induced Hypertension and Gestational Diabetes Mellitus: Two Nested Case-Control Studies |
| Q28087788 | Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm |
| Q100750130 | Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients |
| Q90974949 | Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study |
| Q37267655 | Inhaled corticosteroids in COPD and the risk of serious pneumonia |
| Q34065276 | Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective |
| Q42701518 | Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017. |
| Q35703517 | LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. |
| Q36421917 | Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality |
| Q95641902 | Management of the COPD Patient with Comorbidities: An Experts Recommendation Document |
| Q38835917 | Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective |
| Q36141290 | Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. |
| Q40585360 | Multimorbidity and COPD Medication Receipt Among Medicaid Beneficiaries With Newly Diagnosed COPD. |
| Q34436462 | Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus |
| Q36431478 | Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD. |
| Q47421479 | Parental History of Diabetes, Positive Affect, and Diabetes Risk in Adults: Findings from MIDUS. |
| Q35834906 | Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study |
| Q28070274 | Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review |
| Q53440054 | Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance. |
| Q40235200 | Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study |
| Q91775321 | Predicting asthma attacks in primary care: protocol for developing a machine learning-based prediction model |
| Q90746474 | Prevalence and Risk Factors of ACO (Asthma-COPD Overlap) in Aboriginal People |
| Q36109139 | Prevalence of diagnosed arthritis and arthritis-attributable activity limitation among adults with and without diagnosed diabetes: United States, 2008-2010. |
| Q34551086 | Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis |
| Q36919212 | Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer |
| Q38058413 | Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. |
| Q64122265 | Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease |
| Q38248458 | Safety considerations of inhaled corticosteroids in the elderly. |
| Q38306695 | Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. |
| Q37106582 | Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010 |
| Q48343193 | Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? |
| Q55335157 | Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. |
| Q23916999 | Stepping down asthma treatment: how and when |
| Q35056155 | Systemic effects of inhaled corticosteroids: an overview |
| Q38247488 | Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. |
| Q39579645 | Systemic manifestations of chronic obstructive pulmonary disease |
| Q88495601 | The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System |
| Q44049831 | The WISDOM of inhaled corticosteroids in COPD. |
| Q38598993 | The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study |
| Q93377739 | The dose of inhaled corticosteroids in patients with COPD: when less is better |
| Q36208427 | The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. |
| Q38098479 | The pharmacological approach to the elderly COPD patient |
| Q26739763 | The use of inhaled corticosteroids in pediatric asthma: update |
| Q58694610 | Toward effective prescription of inhaled corticosteroids in chronic airway disease |
| Q35892139 | Transient symptomatic hyperglycaemia secondary to inhaled fluticasone propionate in a young child |
| Q38726082 | Use of inhaled corticosteroids in COPD: improving efficacy. |
| Q92236665 | Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms |
| Q52886323 | [Antidiabetic drugs and drug interactions]. |
Search more.